May 31, 2024 07:00 AM EDTUpdated 02:15 PM
People
Peer Review

Neu­ro­crine CEO Kevin Gor­man to re­tire af­ter 32-year run; Blue­bird picks up fifth CFO in three years

Alex Hoffman

Assistant Editor

Kathy Wong

Editor

Andrew Dunn

Senior Biopharma Correspondent

Af­ter more than three decades at Neu­ro­crine, CEO Kevin Gor­man will re­tire lat­er this year, hand­ing the reins of the $13 bil­lion neu­ro­science drug­mak­er over …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Mer­ck calls ACIP's pneu­mo­coc­cal rec­om­men­da­tion a 'missed op­por­tu­ni­ty,' ad­vo­cates for ex­pand­ing age group

CMS spells out how states can join new cell and gene ther­a­py ac­cess pi­lot

A service from the Financial Times